



IRW

PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-479-C)

In the Application of: )  
 )  
Belardinelli ) Art Unit: 3737  
 )  
Serial No. 10/629,368 )  
 )  
Filed: July 29, 2003 ) Examiner: Not Assigned  
 )  
Title: Myocardial Perfusion Imaging Method )

Commissioner for Patents  
P.O. Box 1450  
Arlington, Virginia 22313-1450

TRANSMITTAL LETTER

Sir:

In regard to the above identified application:

1. We are transmitting herewith the attached:

- a. Supplemental Information Disclosure Statement
- b. Form PTO-1449
- c. Cited Non U.S. Patent References
- d. Return Receipt Postcard

2. With respect to additional fees:


- a. Attached is a check in the amount of \$ -0-

3. Please charge any additional fees or credit overpayment to Deposit Account No.13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 25th day of August, 2004.

Respectfully submitted,

By :

  
A. Blair Hughes  
Reg. No. 32,901



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-479-C)

In the Application of:

Belardinelli

Serial No. 10/629,368

Filed: July 29, 2003

Title: Myocardial Perfusion Imaging Method

Group Art Unit: 3737

Examiner: Not Assigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97-1.98, applicants wish to make the following references of record in the above-identified application. These references may be material to the Examiner's consideration of the presently pending claims. Copies of the non-U.S. Patent references cited below are enclosed along with a completed Form-1449.

**U.S. Patents**

	<u>Patent No.</u>	<u>Inventors</u>	<u>Issue Date</u>
1.	4,956,345	Miyasaka et al.	September 11, 1990
2.	4,968,697	Hutchison	November 6, 1990
3.	5,070,877	Mohiuddin et al.	December 10, 1991
4.	5,189,027	Miyashita et al.	February 23, 1993

McDONNELL BOEHNEN HULBERT & BERGHOFF  
300 South Wacker Drive, 32<sup>nd</sup> Floor  
Chicago, Illinois 60606

	<u>Patent No.</u>	<u>Inventors</u>	<u>Issue Date</u>
5.	5,270,304	Kogi et al.	December 14, 1993
6.	5,459,254	Yamaguchi et al.	October 17, 1995
7.	5,593,975	Cristalli	January 14, 1997
8.	5,705,491	Yamada	January 6, 1998
9.	5,770,716	Khan et al.	June 23, 1998
10.	5,939,543	Morozumi et al.	August 17, 1999
11.	6,214,807	Zablocki et al.	April 10, 2001
12.	US2004/0127533	Hart et al.	July 1, 2004

#### Foreign Patents

	<u>Patent No.</u>	<u>Inventors</u>	<u>Publication Date</u>
1.	WO 93/25677	Pierce	December 23, 1993
2.	WO 00/78779	Zablocki et al.	December 28, 2000
3.	WO 04/011010	Belardinelli et al.	February 5, 2004
4.	EP 0 354 638	Mohuiddin et al.	February 14, 1990
5.	965,411 (Canada)	Marumoto et al.	April 1, 1975
6.	Hei 5[1993]-9197 (Japan)	Matusudo et al.	January 19, 1993

## Other


1. Iskandrian, A, "Adenosine Myocardial Perfusion Imaging", *The Journal of Nuclear Medicine*, vol. 35, pp. 734-736 (1994).
2. Gao, et al., "Novel Short-Acting A<sub>2</sub>A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A<sub>2</sub>A Agonists", *Journal of Pharmacology and Experimental Therapeutics*, vol. 298, pp. 209-218 (2001).
3. Marumoto, et al., "Synthesis and Coronary Vasodilating Activity of 2-Substituted Adenosines", *Chem. Pharm. Bull.* 23(4): 759-774 (1975).
4. Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3',5'-Cyclic Phosphate Analogs", *Chem. Pharm. Bull.* 27(4) 990-1003 (1979).
5. Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", *Bioorganic & Medicinal Chemistry*, 3:1377-1382 (1995).
6. Mager, et al., "Molecular simulation applied to 2-(N'-alkylidenehydrazino)- and 2-(N'-aralkylidenehydrazino) adenosine A<sub>2</sub> Agonists", *Eur J. Med. Chem.* 30:15-25 (1995).
7. Cristalli et al., "2-Alkynyl Derivatives of Adenosine 5'-N'-ethyluronamide: Selective A<sub>2</sub> Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", *J. Med. Chem.* 37:1720-1726 (1994).
8. Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenosines: A Novel Class of Selective Adenosine A<sub>2</sub> Receptor Agonists with Potent Antihypertensive Effects", *J. Med. Chem.* 35:241-252 (1992).

Respectfully submitted,

**McDonnell Boehnen  
Hulbert & Berghoff LLP**

Dated: August 25, 2004

By:

  
A. Blair Hughes  
Reg. No. 32,901

FORM PTO-1449  
(Rev. 2-32)



U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-479-C

Serial No.

10/629,368

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

Belardinelli

**Filing Date:**

7/29/03

**Group:**

3737

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	4,956,345	9/11/90	Miyasaka et al			
	4,968,697	11/6/90	Hutchison			
	5,070,877	12/10/91	Mohiuddin et al			
	5,189,027	2/23/93	Miyashita et al.			
	5,270,304	12/14/93	Kogi et al			
	5,459,254	10/17/95	Yamaguchi et al.			
	5,593,975	1/14/97	Cristalli			
	5,705,491	1/6/98	Yamada			
	5,770,716	6/23/98	Khan et al.			
	5,939,543	8/17/99	Morozumi et al.			
	6,214,807	4/10/01	Zablocki et al.			
	US2004/0127533	7/1/04	Hart et al.			

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 93/25677	12/13/93	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

02-479-C

Serial No.

10/629,368

Applicant:

Belardinelli

Filing Date:

7/29/03

Group:

3737

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		WO 00/78779	12/28/00	PCT				
		WO 04/011010	2/5/04	PCT				
		EP 0354 638	2/14/90	EP				
		965,411	4/1/75	CA				
		Hei 5[1993]-9197	1/19/93	JP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Iskandrian, A, "Adenosine Myocardial Perfusion Imaging", <i>The Journal of Nuclear Medicine</i> , vol. 35, pp. 734-736 (1994).
	Gao, et al., "Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists", <i>Journal of Pharmacology and Experimental Therapeutics</i> , vol. 298, pp. 209-218 (2001).
	Marumoto, et al., "Synthesis and Coronary Vasodilating Activity of 2-Substituted Adenosines", <i>Chem.. Pharm. Bull.</i> 23(4): 759-774 (1975).
	Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3',5'-Cyclic Phosphate Analogs", <i>Chem.. Pharm. Bull.</i> 27(4) 990-1003 (1979).
	Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", <i>Bioorganic &amp; Medicinal Chemistry</i> , 3:1377-1382 (1995).
	Mager, et al., "Molecular simulation applied to 2-(N'alkylidenehydrazino)- and 2-(N'-aralkylidenehydrazino) adenosine A <sub>2</sub> Agonists", <i>Eur J. Med. Chem.</i> 30:15-25 (1995).
	Cristalli et al., "2-Alkynyl Derivatives of Adenosine 5'-N'ethyluronamide: Selective A <sub>2</sub> Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", <i>J. Med. Chem.</i> 37:1720-1726 (1994).
	Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenosines: A Novel Class of Selective Adenosine A <sub>2</sub> Receptor Agonists with Potent Antihypertensive Effects", <i>J. Med. Chem.</i> 35:241-252 (1992).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.